Literature DB >> 6688326

Radiation therapy for Graves' disease.

M W Brennan, C R Leone, L Janaki.   

Abstract

We used radiation therapy (a total of 2,000 rads) to treat 14 patients (three men and 11 women, ranging in age from 27 to 72 years) with Graves' disease. Three of these patients had refused to take corticosteroids and the other 11 had failed to respond to them, had experienced side effects, or had other contraindications to their use. After follow-up periods ranging from six months to three years, soft-tissue inflammation was reduced in 13 of the 14 patients. All but two patients showed a decrease in proptosis of 1 to 3 mm. Myopathy showed the least improvement. Although we noted transient eyelid erythema, there were no permanent sequelae and none of the patients has had a recurrence of the inflammation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6688326     DOI: 10.1016/s0002-9394(14)77787-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  The antiproliferative effect of fractionized radiation therapy: optimization of dosage.

Authors:  M Velikay; U Stolba; A Wedrich; P Datlinger; J Akramian; S Binder
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

2.  Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study.

Authors:  S Binder; M Bonnet; M Velikay; J P Gerard; U Stolba; A Wedrich; H Hohenberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

3.  Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

Authors:  C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Lepri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

4.  [Endocrine orbitopathy: comparison of the long-term result and classification after radiotherapy].

Authors:  M H Seegenschmiedt; L Keilholz; G Gusek-Schneider; S Barth; J Hensen; F Wolf; G O Naumann; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-09       Impact factor: 4.033

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.